<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647256</url>
  </required_header>
  <id_info>
    <org_study_id>VFCE-2011-004</org_study_id>
    <nct_id>NCT01647256</nct_id>
  </id_info>
  <brief_title>Comparison of Nikkomycin Z Bioavailability Under Fed and Fasting Conditions</brief_title>
  <official_title>Comparison of Nikkomycin Z Bioavailability After Single Dose Administration Under Fed (High Fat Meal) Compared to Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate if eating a high fat meal versus not eating&#xD;
      any food affects how the study drug (Nikkomycin Z) is absorbed into the body. The second&#xD;
      purpose is to gain further information about the safety of Nikkomycin Z in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the single-dose bioavailability of Nikkomycin Z 500 mg (two 250 mg capsules) under&#xD;
      fed and fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient # subjects available for 2nd group; evaluating alternate study site&#xD;
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and extent of Nikkomycin Z absorption under fed and fasting conditions</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of Nikkomycin Z urinary excretion</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Nikkomycin Z fed - fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:&#xD;
Day 1: Nikkomycin Z 500 mg with high fat breakfast&#xD;
Period 2:&#xD;
Day 1: Nikkomycin Z 500 mg under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nikkomycin Z fasting - fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:&#xD;
Day 1: Nikkomycin Z 500 mg under fasted conditions&#xD;
Period 2:&#xD;
Day 1: Nikkomycin Z 500 mg with high fat breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nikkomycin Z</intervention_name>
    <description>Capsule, 500 mg, single-dose</description>
    <arm_group_label>Nikkomycin Z fasting - fed</arm_group_label>
    <arm_group_label>Nikkomycin Z fed - fasting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 18 years of age and not over 40 years of age&#xD;
&#xD;
          -  Be male, or female (non childbearing potential or using adequate contraception)&#xD;
&#xD;
          -  Have a body mass index between 18 and 29 kg/m2&#xD;
&#xD;
          -  Able to understand the study and give written informed consent&#xD;
&#xD;
          -  Be determined healthy based on a medical and laboratory evaluation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under the age of 18 years or over 40 years of age&#xD;
&#xD;
          -  Current smoker or history of smoking within 3 months of participation&#xD;
&#xD;
          -  Inability to comprehend study and provide written informed consent&#xD;
&#xD;
          -  Inability to comply with the study requirements&#xD;
&#xD;
          -  History of or current evidence of major organ disease&#xD;
&#xD;
          -  Renal disease - serum creatinine &gt; 1.5 mg/dL, significant hematuria or proteinuria,&#xD;
             known structural abnormality or chronic kidney disease&#xD;
&#xD;
          -  Hepatic disease - active viral hepatitis, history of hepatitis B or hepatitis C,&#xD;
             bilirubin &gt; 2.0, ALT or AST above normal upper limit for laboratory, alcoholic liver&#xD;
             disease, other chronic liver disease&#xD;
&#xD;
          -  CNS disease or cognitive dysfunction - any past history of epilepsy, CNS infections,&#xD;
             stroke, CNS bleed, severe headaches, major psychiatric illness, or current mental&#xD;
             status changes&#xD;
&#xD;
          -  Lung disease - history of severe asthma, COPD, pulmonary tuberculosis, or other major&#xD;
             lung disease&#xD;
&#xD;
          -  Cardiac disease - history or current evidence of ischemic coronary artery disease,&#xD;
             myocardial infarction, heart failure, or significant arrhythmia&#xD;
&#xD;
          -  Gastrointestinal disease - presence of inflammatory bowel disease, difficulty&#xD;
             swallowing, or any gastrointestinal probably that would limit taking oral medications&#xD;
             or that may compromise absorption of oral medications&#xD;
&#xD;
          -  Cancer - History of hematologic malignancy or solid tumor excluding basal cell&#xD;
             carcinoma limited to the skin within the past 5 years&#xD;
&#xD;
          -  History of autoimmune or inflammatory disease such as rheumatoid arthritis and lupus&#xD;
&#xD;
          -  Immunocompromised state - solid organ transplant, cancer chemotherapy, stem cell&#xD;
             transplant with graft versus host disease, immunosuppressive therapy, or HIV infection&#xD;
&#xD;
          -  Recent weight loss of greater than 10%&#xD;
&#xD;
          -  Any other history or evidence of disease that in the opinion of the physician would&#xD;
             increase the risk for the subject for clinical trial participation&#xD;
&#xD;
          -  Regular use of prescription medications, over-the-counter medications, or&#xD;
             dietary/herbal supplements within 14 days of day 1. Occasional use of acetaminophen or&#xD;
             over-the-counter NSAID within the 14 day window may be allowed at the P.I. discretion&#xD;
&#xD;
          -  Subjects who received another investigational drug within 30 days of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn R Matthias, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David E Nix, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona - Clinical and Translational Science Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2012</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Fed</keyword>
  <keyword>Fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nikkomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

